Home / Funds / Voleon Capital Management LP
Voleon Capital Management LP
The short positions this fund discloses today, across every market.
8 open positions
4 Markets
July 21, 2026 Last disclosure
549300EJ1ZB4YYIOMD56 LEI
| Issuer | Market | % of capital | Since |
|---|---|---|---|
| Zealand Pharma A/S | Denmark | 1.11% | May 19, 2026 |
| B&M European Value Retail S.A. | Germany | 0.79% | April 20, 2026 |
| Oryzon Genomics, S.A. | Spain | 0.63% | July 3, 2026 |
| Gubra A/S | Denmark | 0.59% | March 23, 2026 |
| Lang & Schwarz Aktiengesellschaft | Germany | 0.59% | February 2, 2022 |
| Tubacex, S.A. | Spain | 0.59% | June 30, 2026 |
| Medigene AG | Germany | 0.55% | December 4, 2017 |
| Atos Group | France | 0.50% | July 21, 2026 |
History of disclosures
| Date | Issuer | Market | % of capital | End of publication |
|---|---|---|---|---|
| April 12, 2023 | Nokian Renkaat | Finland | 0.76% | still open |
| April 6, 2023 | Hansa Biopharma AB | Sweden | 0.53% | still open |
| April 5, 2023 | Fugro N.V. | Netherlands | 0.58% | still open |
| April 5, 2023 | Zealand Pharma A/S | Denmark | 0.45% | April 5, 2023 |
| April 4, 2023 | Zealand Pharma A/S | Denmark | 0.50% | April 4, 2023 |
| April 4, 2023 | Saipem SPA | Italy | 0.33% | still open |
| April 3, 2023 | Euroapi | France | 0.70% | July 3, 2023 |
| March 30, 2023 | Nokian Renkaat | Finland | 0.80% | still open |
| March 30, 2023 | Saipem SPA | Italy | 0.68% | still open |
| March 30, 2023 | Laboratorios Farmaceuticos Rovi, S.A. | Spain | 0.47% | still open |
| March 28, 2023 | Laboratorios Farmaceuticos Rovi, S.A. | Spain | 0.51% | still open |
| March 27, 2023 | QT Group | Finland | 0.49% | still open |
| March 23, 2023 | Nokian Renkaat | Finland | 0.79% | still open |
| March 21, 2023 | Hansa Biopharma AB | Sweden | 0.50% | still open |
| March 20, 2023 | Nokian Renkaat | Finland | 0.81% | still open |
| March 17, 2023 | Euroapi | France | 0.61% | July 3, 2023 |
| March 17, 2023 | Fugro N.V. | Netherlands | 0.61% | still open |
| March 15, 2023 | Nokian Renkaat | Finland | 0.70% | still open |
| March 14, 2023 | Nokian Renkaat | Finland | 0.66% | still open |
| March 13, 2023 | Saipem SPA | Italy | 0.84% | still open |
| March 10, 2023 | Fugro N.V. | Netherlands | 0.54% | still open |
| March 10, 2023 | Euroapi | France | 0.52% | July 3, 2023 |
| March 10, 2023 | Nokian Renkaat | Finland | 0.50% | still open |
| March 8, 2023 | Saipem SPA | Italy | 0.70% | still open |
| March 7, 2023 | Fugro N.V. | Netherlands | 0.60% | still open |
| March 3, 2023 | Saipem SPA | Italy | 0.61% | still open |
| March 1, 2023 | Oncopeptides AB | Sweden | 0.68% | still open |
| March 1, 2023 | Solutions 30 SE | France | 0.47% | March 3, 2023 |
| February 28, 2023 | QT Group | Finland | 0.51% | still open |
| February 27, 2023 | Saipem SPA | Italy | 0.55% | still open |
| February 24, 2023 | Oncopeptides AB | Sweden | 0.76% | still open |
| February 24, 2023 | Fugro N.V. | Netherlands | 0.50% | still open |
| February 22, 2023 | Laboratorios Farmaceuticos Rovi, S.A. | Spain | 0.39% | still open |
| February 21, 2023 | Oncopeptides AB | Sweden | 0.88% | still open |
| February 21, 2023 | Laboratorios Farmaceuticos Rovi, S.A. | Spain | 0.51% | still open |
| February 17, 2023 | Oncopeptides AB | Sweden | 0.98% | still open |
| February 15, 2023 | Oncopeptides AB | Sweden | 1.09% | still open |
| February 8, 2023 | Oncopeptides AB | Sweden | 1.10% | still open |
| February 6, 2023 | Solutions 30 SE | France | 0.53% | March 3, 2023 |
| February 3, 2023 | Oncopeptides AB | Sweden | 1.09% | still open |
| February 2, 2023 | Solutions 30 SE | France | 0.48% | February 6, 2023 |
| January 30, 2023 | Sinch AB (publ) | Sweden | 0.51% | still open |
| January 24, 2023 | Oncopeptides AB | Sweden | 1.19% | still open |
| January 19, 2023 | Oncopeptides AB | Sweden | 1.20% | still open |
| January 18, 2023 | Oncopeptides AB | Sweden | 1.19% | still open |
| January 11, 2023 | Oncopeptides AB | Sweden | 1.29% | still open |
| January 11, 2023 | Sinch AB (publ) | Sweden | 0.57% | still open |
| January 10, 2023 | Solutions 30 SE | France | 0.58% | February 6, 2023 |
| January 3, 2023 | Oncopeptides AB | Sweden | 1.38% | still open |
| January 3, 2023 | Solutions 30 SE | France | 0.67% | February 6, 2023 |
The funds short on the same companies
- Citadel Advisors LLC 2 companies in common
- AHL Partners LLP 1 company in common
- ActusRayPartners Limited 1 company in common
- Capital Fund Management 1 company in common
- Citadel Advisors II LLC 1 company in common
- Connor Clark & Lunn Investment Management Ltd 1 company in common
- D. E. Shaw & Co., L.P. 1 company in common
- GSA Capital Partners LLP 1 company in common
- Jennison Associates LLC 1 company in common
- Jupiter Asset Management Limited 1 company in common
- Marshall Wace LLP 1 company in common
Cite this page
The figure comes from the regulator register, not from this site. Quoting both lets your reader check it.
QuiVad, Voleon Capital Management LP, data as at July 21, 2026, https://www.quivad.com/detenteur/voleon-capital-management-lp?page=29